Analyst Ratings for Myriad Genetics (MYGN) [Buys]
MYGN Rating Summary
MYGN Price Target Summary
- Highest: $38.00 (Stephens)
- Lowest: $22.00 (Dougherty & Co)
- Average: $29.75
Overall Rating:
NEUTRAL
Rating Trend:
=
Avg. $ Target:
$29.75 (-7.7%)
| Date | Firm | Type | Rating (Past) |
PT (Past) |
Start $ | End $ | % Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 5/9/2013 | Stephens | New Coverage | Overweight (N/A) |
38.00 (N/A) |
30.63 | 32.24 | 5.26% | Details |
| 5/8/2013 | Mizuho Securities | Upgrade | Buy (Neutral) |
34.00 (27.00) |
28.30 | 32.24 | 13.92% | Details |
| 10/24/2012 | BofA/Merrill Lynch | Upgrade | Buy (Neutral) |
N/A (N/A) |
25.37 | 32.24 | 27.08% | Details |
| 10/2/2012 | Cowen | New Coverage | Outperform (N/A) |
N/A (N/A) |
27.40 | 32.24 | 17.66% | Details |
| 10/1/2012 | Piper Jaffray | Upgrade | Overweight (Neutral) |
35.00 (28.00) |
26.95 | 32.24 | 19.63% | Details |
| 5/21/2012 | Leerink Swann | Upgrade | Outperform (N/A) |
31.00 (N/A) |
24.54 | 32.24 | 31.38% | Details |
| 11/2/2011 | Ticonderoga | Upgrade | Buy (N/A) |
25.00 (N/A) |
20.33 | 32.24 | 58.58% | Details |
| 9/12/2011 | Auriga » Updated 5/22/2012 |
Upgrade | Buy (N/A) |
31.00 (N/A) |
0.00 | 32.24 | 0% | Details |
| 3/11/2011 | Jefferies » Updated 3/4/2013 |
New Coverage | Buy (N/A) |
31.00 (33.00) |
18.54 | 32.24 | 73.89% | Details |
| 10/13/2010 | RBC Capital | Upgrade | Outperform (N/A) |
N/A (N/A) |
18.66 | 32.24 | 72.78% | Details |
